Skip to main content
Premium Trial:

Request an Annual Quote

IntegriDerm Gets NIH Grant to Develop GI Tract Microarray


  IntegriDerm, the Huntsville, Ala., manufacturer of specialized DermArray, is going under the skin to develop a specialized gastrointestinal DNA array.

The development will be funded by a $147,650 National Institutes of Health Small Business Innovation Research Phase I grant the company was awarded last week.

In this project, the company will be using a proprietary computer-assisted approach it used to select the genes for its nylon-based DermArray, which includes 4,400 skin-disease related genes, and PharmArray, which includes genes relevant to drug targets, said Tom Dooley, CEO of IntegriDerm. The new array will sell for $1,580 per nylon membrane. Each membrane can be reused five times.

This new chip signals IntegriDerm’s strategy to capture specialized markets within the array sector. “A lot of other companies have broad strategies to screen as many genes as they can, but ours is to take a small niche area and stick with it,” said Dooley. “In the gastroenterology field there isn’t really a product on the market, and our objective is to capture the same kinds of clients we have with the dermatology array.”

The company has hired Ernest Curto, a gastroenterology specialist from the University of Alabama at Birmingham, as a principal investigator on the grant.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more